Advanced Recurrent Ovarian Cancer Market Size (2024 – 2030)

The Advanced Recurrent Ovarian Cancer Market was valued at USD 3.70 billion in 2023 and is projected to reach a market size of USD 5.79 billion by the end of 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 6.6%. 

Key Market Insights:

The quantity of ladies determined to have ovarian disease keeps on rising, adding to the expanded interest in treatment choices. As per the World Malignant Growth Exploration Asset Global (WCRF), ovarian disease is the eighth most common disease in ladies around the world. It causes a bigger number of passings each year than some other gynaecological malignant growth. In 2020, around 313,000 new cases and 207,252 passings were accounted for around the world. Besides, the gamble of ovarian disease is expanded in females with conditions like not bearing youngsters, untimely menarche (not exactly the age of 12), deferring in regular menopause (post the age of 55), smoking, chemical treatment, and family ancestry. Singapore receives almost 500,000 medical tourists with Indonesia resulting in half of them, every year. The rising reception of novel medications is adding to the development of the ovarian disease drug market. Medical services suppliers and patients are more disposed to take on these therapies because of their superior viability and decreased aftereffects. Besides, the accessibility of a hearty improvement pipeline guarantees a persistent convergence of creative treatment choices. As indicated by Aravive, Batiraxcept was permitted quick track assignment by the U.S. Food and Medication Organization (FDA) for platinum-safe ovarian disease and clear cell renal cell carcinoma.

Advanced Recurrent Ovarian Cancer Market Drivers:

The growing prevalence of ovarian cancer is driving the demand for advanced solutions:

The global ovarian cancer market is influenced by the rising prevalence of ovarian cancer. One of the most common types of cancer is ovarian cancer. According to the World Health Organization (WHO), Organization, thousands of new cases are diagnosed each. Changing lifestyle patterns and the aging population have contributed to the rising incidence of ovarian cancer. As the population ages, the risk of developing ovarian cancer increases, further intensifying the demand for effective treatment options. Extensive research and development efforts by pharmaceutical companies and research institutions have been spurred by the surge in ovarian cancer cases.

Medical technology and personalized medicine have improved augmenting the market for the global advanced recurrent ovarian cancer market.

A new era in the management of ovarian cancer has been created by the advancement of medical technology and personalized medicine. Early detection and accurate diagnosis of ovarian cancer is possible thanks to the evolution of diagnostic tools. The chances of detecting ovarian cancer at its early stages have been improved by the use of transvaginal ultrasounds, magnetic resonance images, and CA-125.

Implementation of favorable reimbursement policies driving the market:

Favourable reimbursement policies and the expansion of healthcare infrastructure have led to the growth of the ovarian cancer market. Governments and healthcare authorities in various countries are increasing their investment in healthcare facilities. Improved patient access to healthcare services, diagnosis, and treatment for ovarian cancer is a result of this development.

The financial burden on patients seeking cancer treatments has been alleviated by favourable reimbursement policies. Treatment has become more affordable and accessible due to reimbursement support for diagnostic tests, surgeries, and targeted therapies.

The increasing governmental investment in medical infrastructure and maintenance is fuelling the Advanced Recurrent Ovarian Cancer Market growth.

Increasing governmental investment in medical infrastructure and maintenance is driving the growth of the Advanced Recurrent Ovarian Cancer (AROC) market. Improved diagnosis and treatment options, expanded access to care, enhanced patient support systems, increased public awareness, and the promotion of precision medicine are some of the positive outcomes of these investments. As a result of these factors, the AROC market is expected to continue to grow, with new and more effective treatments being developed to combat this challenging disease.

Advanced Recurrent Ovarian Cancer Market Restraints and Challenges:

The high cost of ovarian cancer treatment can make it hard for many patients to get it. Chemo, targeted therapies, and surgery can cost a lot and many patients need supportive care.

There are a limited number of effective therapies for advanced recurrent ovarian cancer. The majority of patients will eventually relapse, and there are few options available for second-line and third-line treatment.

It is more difficult to treat ovarian cancer at a late stage. There is not enough awareness about the symptoms of ovarian cancer and the importance of early detection.

ADVANCED RECURRENT OVARIAN CANCER MARKET REPORT COVERAGE:

Advanced Recurrent Ovarian Cancer Market Segmentation: By Treatment Type

• Targeted Therapy

• Chemo Therapy

• Surgery

• Radiation

• Biological Therapy

The targeted therapy segment had the largest revenue share in 2023. Targeted treatments are intended to explicitly recognize and go after malignant growth cells while saving healthy cells, bringing about more compelling treatment with fewer secondary effects. Targeted therapies aim to stop the growth of cancer cells. Ovarian cancer patients who receive bevacizumab as a targeted therapy are shown to shrink and slow the growth of their tumours.

Over the forecast period, the radiation therapy segment is expected to grow at the fastest rate. Radiation therapy uses X-rays which are used to kill cancer cells. The procedure only targets the area affected by the cancer. Radiation therapy is beneficial in treating cancer that has spread to other parts of the body, such as the spine and brain. Women with ovarian cancer are more likely to receive external beam radiation therapy.

Advanced Recurrent Ovarian Cancer Market Segmentation: By End-User

• Hospitals

• Clinics

• Pharmacies

In 2023, hospitals dominated the global market and accounted for the highest market share of around 45.3%. The dominance of the segment is because hospital pharmacies ensure timely access to necessary drugs for patients undergoing ovarian cancer treatment, which is essential for their care. Patients who are treated for ovarian cancer in hospitals have increased trust in hospital pharmacies contributing to the growth of the segment. The online pharmacy material segment is estimated to register the fastest growth over the forecast period. Drugs used in the treatment of ovarian cancer can be found in the digital pharmacy. The growth over the forecast period is attributed to the convenience of ordering prescriptions online, which eliminates the need for physical visits. Clinics are the fastest-growing sector after the breakdown of COVID-19.

Advanced Recurrent Ovarian Cancer Market Segmentation: Regional Analysis

• North America

• Asia-Pacific

• Europe

• South America

• Middle East and Africa

In 2023, the North American region dominated the Advanced Recurrent Ovarian Cancer Market with a revenue of 43.2%. The region has a well-developed healthcare infrastructure and advanced medical facilities, which allow early diagnosis and treatment of ovarian cancer. Increased awareness among patients has led to increased screening and detection rates. Many pharmaceutical companies, research institutions, and academic centres are located in North America. Ovarian cancer is fifth in cancer death among women. Gynaecologic malignancies are the most lethal of all. Ovarian cancer was diagnosed in 19,710 women and 13,270 deaths were reported in the U.S.

The fastest-growing region is Asia Pacific. The increasing prevalence of ovarian cancer in Asian countries is one of the reasons for the growth over the forecast period. Market growth can be attributed to the rising prevalence of ovarian cancer and the demand for effective treatment options. Increasing focus on healthcare infrastructure development in the Asia–Pacific region fuels the demand for ovarian cancer drugs.

COVID-19 Impact Analysis on the Advanced Recurrent Ovarian Cancer Market:

With the emergence of the COVID-19 outbreak, ovarian cancer is experiencing higher than anticipated demand in all regions compared to pre-pandemic levels. Demand returning to pre-pandemic levels is the reason for the sudden spike in CAGR. Most of the market growth was affected by the disruption to clinical trials and the outbreak of COVID-19. The market is difficult to administer. Clinics were full of COVID-19 patients and several treatments were performed outside of the clinic.

Latest Trends/ Developments:

The latest trend that is being followed in the Advanced Recurrent Ovarian Cancer Market is the usage of Electrochemical Nanosensors. There are promising methodologies and roles for accurate biomarker detection in OC, and they typically have the detection capacity for biomarkers in minute amounts and other analytes. In 75% of patients, current diagnostic methods have led to the detection of CA-125 indicators at low concentrations could lead to improved early detection and diagnosis.

The inclusion of Optical nanosensors in the Advanced Recurrent Ovarian Cancer Market is the usage of Electrochemical Nanosensors. The incorporated optical transducer system makes optical biosensors a flexible analysis tool. The main objective of an optical biosensors is to transmit a signal proportional to a selected agent.

Key Players:

1. IMV

2. Elucida Oncology

3. Klus Pharma

4. Chia Tai Tianqing Pharmaceutical Group

5. Sumitomo Pharma Oncology

6. Precigen, Inc

7. Glycotope GmbH

• In September 2022, AstraZeneca and Merck introduced that Lynparza (olaparib) has been permitted in China for the renovation/maintenance treatment of adult patients with superior epithelial ovarian, fallopian tube, or primary peritoneal cancer who're in entire or partial reaction to 1st-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is related to homologous recombination deficiency (HRD)-superb repute.

• In September 2022, Pfizer and Strata Oncology have enlarged their partnership for a medical trial assessing diverse cancer therapies in new, biomarker-guided affected person agencies.